Osteosarcoma, a malignant bone tumor predominately affecting adolescents, remains a therapeutic challenge due to its aggressive nature and propensity for metastasis. Conventional chemotherapeutic regimens such as cisplatin (CDDP) provide some clinical benefit but are often culpable for severe side effects and eventual drug resistance. This urgent clinical impasse has propelled investigations into adjunct therapies with enhanced efficacy and tolerability. YHD has been clinically recognized for decades for its therapeutic potential, but its molecular underpinnings in OS treatment remained obscure until now.

The researchers employed a comprehensive network pharmacology approach that identified 67 bioactive constituents within YHD. Among these, (-)-epicatechin and aucubin emerged as principal compounds with high target engagement. The integrated target prediction delineated 101 overlapping OS-associated molecular targets, largely involving pivotal oncogenic regulators such as AKT1, TP53, MAPK14, and CASP3. Enrichment analyses spotlighted the PI3K/AKT and MAPK signaling pathways as the principal conduits mediating YHD’s therapeutic action.

Molecular docking simulations underscored the robust binding affinities between YHD’s active ingredients and key OS protein targets, confirming the compound-target interactions postulated by the network pharmacology framework. Notably, the docking heatmap revealed darker blue shading correlating with more stable binding free energies, highlighting the structural compatibility and potential inhibitory potency of these phytochemicals on oncogenic targets.

Cellular functional assays further elucidated YHD’s selective cytotoxic profile. Remarkably, YHD inhibited proliferation, migration, and invasion of osteosarcoma cells without compromising viability in normal human liver (LO2) and kidney (HK2) cell lines. The reduction of the proliferation marker PCNA and the induction of G2/M cell cycle arrest, mediated by downregulated cyclin B expression, pinpoint mechanistic checkpoints through which YHD impedes tumor growth.

Exploring the metastatic cascade, YHD modulated the epithelial-mesenchymal transition (EMT) by downregulating transcription factors and proteins such as Snail, Vimentin, and N-cadherin, while restoring E-cadherin expression. This molecular switch impairs OS cells’ invasive capabilities and disrupts matrix remodeling through attenuation of matrix metalloproteinases (MMPs), fundamentally curtailing metastatic potential.

Central to YHD’s antitumor efficacy is its induction of reactive oxygen species (ROS)-mediated mitochondrial dysfunction. YHD treatment precipitated a significant increase in intracellular ROS, catalyzing a decline in mitochondrial DNA copy number, destabilization of mitochondrial membrane potential, and consequential inhibition of ATP synthesis. This mitochondrial distress activated intrinsic apoptotic pathways as evidenced by the release of cytochrome c, followed by sequential activation of caspase-9, caspase-3, and PARP cleavage, culminating in programmed cancer cell death.

Mechanistic interrogation revealed that YHD concurrently suppresses the oncogenic PI3K/AKT signaling cascade while activating the stress-responsive p38 MAPK pathway. Western blot analyses highlighted decreased phosphorylation of PI3K and AKT alongside an upregulation of phosphorylated p38 MAPK in OS cells treated with YHD. The roles of these pathways were further substantiated by pharmacological manipulation: a PI3K activator and a p38 inhibitor partially rescued cell viability and migration impeded by YHD, verifying their critical regulatory functions.

Translating these in vitro findings, orthotopic osteosarcoma mouse models treated with YHD demonstrated markedly reduced primary tumor volume and diminished lung metastatic foci, affirming YHD’s potent antineoplastic capacity in vivo. Strikingly, combining YHD with cisplatin resulted in a synergistic inhibition of tumor progression and metastasis, underscoring YHD’s utility in sensitizing OS cells to chemotherapy and mitigating chemoresistance.

This comprehensive study not only unveils the molecular intricacies of YHD’s anti-osteosarcoma activity but also positions YHD as a promising adjuvant therapeutic candidate that could revolutionize OS clinical management. By harnessing the power of traditional medicinal compounds and integrating modern molecular insights, the therapeutic landscape for osteosarcoma could be significantly augmented.

Future clinical trials and translational studies are warranted to validate these preclinical observations and optimize YHD formulations for human application. The potential of YHD to reduce chemotherapy-associated toxicity while enhancing antitumor efficacy represents a pivotal advancement in holistic cancer treatment paradigms.

In summary, Yanghe Decoction exerts its therapeutic effects against osteosarcoma through a multifaceted mechanism involving ROS-induced mitochondrial dysfunction, strategic suppression of the PI3K/AKT pathway, and activation of p38 MAPK signaling. This integrative molecular modulation culminates in decreased tumor proliferation, invasion, and metastasis, alongside enhanced chemotherapy response, heralding a novel era for TCM-derived therapeutics in oncological precision medicine.

Subject of Research: Osteosarcoma treatment via traditional Chinese medicine (Yanghe Decoction) elucidating molecular mechanisms.

Article Title: Network pharmacology reveals that Yanghe Decoction inhibits osteosarcoma progression via ROS-induced mitochondrial dysfunction and enhances cisplatin sensitivity.

Web References: Available through ScienceDirect: https://www.sciencedirect.com/journal/genes-and-diseases

References:
Huang Y, Tang D, Zhao R, Zhang J, Qu X, Li N, Ren Y, Luo X. Network pharmacology reveals that Yanghe Decoction inhibits osteosarcoma progression via ROS-induced mitochondrial dysfunction and enhances cisplatin sensitivity. Genes & Diseases. DOI: 10.1016/j.gendis.2025.101862.

Image Credits: Yanran Huang, Dagang Tang, Runhan Zhao, Jun Zhang, Xiao Qu, Ningdao Li, Yi Ren, Xiaoji Luo

Keywords: Osteosarcoma, Yanghe Decoction, Traditional Chinese Medicine, ROS, Mitochondrial Dysfunction, PI3K/AKT Pathway, p38 MAPK, Molecular Docking, Chemotherapy Sensitization, Apoptosis, Cell Cycle Arrest, Metastasis Inhibition

Enzalutamide, an androgen receptor inhibitor, has been a cornerstone in resistance management strategies for metastatic castration-resistant prostate cancer (mCRPC). However, its efficacy is often undermined by various biological factors, through which cancer cells adapt and develop resistance. This study highlights PDGFC as a significant player in this adaptive mechanism, providing a new focus for therapeutic intervention.

The researchers utilized both in vitro and in vivo models to substantiate their claims regarding PDGFC’s involvement in prostate cancer proliferation and survival. They meticulously demonstrated that the expression levels of PDGFC were significantly elevated in enzalutamide-resistant prostate cancer cell lines compared with sensitive counterparts. Such an increase suggests that PDGFC may promote tumor survival even in the presence of the therapy designed to inhibit cancer cell growth.

Moreover, the study delves into the cellular mechanisms underpinned by PDGFC that facilitate this resistance. The activation of the Rap1-MAPK signaling pathway represents a pivotal discovery, whereby PDGFC enhances cellular proliferation and diminishes apoptosis, effectively fostering an environment conducive to cancer survival. Understanding this pathway is crucial as it opens avenues for therapeutic targeting, potentially overcoming the barriers presented by enzalutamide resistance.

The implications of these findings extend beyond mere mechanistic understanding; they provoke a reevaluation of current treatment protocols. By targeting the PDGFC-Rap1-MAPK axis specifically, clinicians could devise combinatorial therapies that not only inhibit androgen receptor signaling but also disrupt the compensatory pathways that tumors exploit during treatment. This study emboldens the notion of personalized medicine, wherein therapies can be tailored based on the unique molecular profiles of patients’ tumors.

What stands out in this research is the promising data indicating that silencing PDGFC in resistant cell lines led to reduced cell growth and increased sensitivity to enzalutamide. This underscores the therapeutic potential of PDGFC inhibition, raising the prospect of developing new pharmacological agents that target this growth factor. As resistance becomes an ubiquitous issue in cancer therapy, such targeted treatments could revolutionize the landscape of prostate cancer management.

In addition to preclinical models, the authors also explored the clinical relevance of their findings. An analysis of prostate cancer patient samples indicated a correlation between PDGFC expression levels and poor clinical outcomes. This correlation cements PDGFC’s status not only as a therapeutic target but also as a potential biomarker for predicting treatment response in prostate cancer patients.

The authors acknowledged the multifaceted nature of cancer resistance and supported their findings by cross-referencing data from previous studies, thereby positioning their work within the broader context of ongoing research. This collaborative spirit is essential in cancer research, where findings from diverse studies can converge to yield a more comprehensive understanding of tumor behavior and response to therapy.

Clinical trials aiming to evaluate PDGFC inhibition alongside conventional therapies are anticipated as the next logical step. Such trials would need to assess not only the safety and efficacy of PDGFC-targeting agents but also define patient populations that would most benefit from this strategy. Biomarker-driven trial designs may provide additional insights, ensuring that those with the highest PDGFC expression can be prioritized for these innovative treatment approaches.

Understanding the intricacies of tumor microenvironments is another frontier this research touches upon. PDGFC is known to interact with various cell types within the tumor stroma, potentially influencing not only cancer cell behavior but also the entire tumor ecology. Future investigations should consider how manipulating the PDGFC-Rap1-MAPK pathway might affect not just cancer cells, but also the immune environment and stromal interactions, which are crucial underpinnings of tumor progression.

Ultimately, as research continues to elucidate the roles of various oncogenic factors in prostate cancer, it becomes increasingly apparent that a multi-faceted approach is mandatory. The promising revelations about PDGFC provide a vital piece in the puzzle of enzalutamide resistance, indicating that progress in overcoming therapeutic challenges is feasible.

As we forge ahead, the integration of such insights into clinical practice will require robust frameworks and collaboration across various disciplines within medical science. The rising narrative that happens when molecular discoveries translate into actionable clinical strategies provides hope for improved outcomes in prostate cancer management.

As this dynamic field evolves, the findings of Deng et al. may pave the way for revolutionary changes in how resistance mechanisms are targeted, ensuring a more hopeful outlook for patients grappling with advanced prostate cancer. This paradigm shift not only emphasizes the importance of continuing research but also highlights the critical nature of integrating scientific discoveries into methods that improve patient care and survival rates.

The research led by Deng, Chen, and Zhong underscores the significance of investigating newer pathways in cancer biology and their role in therapeutic resistance. This avenue holds promise for innovative strategies that could ultimately enhance the effectiveness of existing treatments and lead to better prognoses for individuals affected by this devastating disease.

By continuing to unravel the complexities of cancer pathways and their interactions, scientists can aspire to leverage knowledge into tangible benefits for patient outcomes, marking the dawn of a new era in cancer treatment and management.

Subject of Research: Mechanisms of enzalutamide resistance in prostate cancer through PDGFC and the Rap1-MAPK pathway.

Article Title: PDGFC facilitates enzalutamide resistance in prostate cancer through activation of the Rap1-MAPK pathway.

Article References: Deng, B., Chen, S., Zhong, D. et al. PDGFC facilitates enzalutamide resistance in prostate cancer through activation of the Rap1-MAPK pathway. J Cancer Res Clin Oncol 151, 267 (2025). https://doi.org/10.1007/s00432-025-06276-w

Image Credits: AI Generated

DOI:

Keywords: PDGFC, enzalutamide resistance, prostate cancer, Rap1-MAPK pathway, personalized medicine.